-
EP3055695
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3055695
| EP3055695 - METHOD FOR IN VITRO QUANTIFYING ALLO-ANTIBODIES, AUTO-ANTIBODIES AND/OR THERAPEUTIC ANTIBODIES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 05.04.2019 Database last updated on 02.11.2024 | |
| Former | Examination is in progress Status updated on 20.03.2017 | Most recent event Tooltip | 05.04.2019 | Application deemed to be withdrawn | published on 08.05.2019 [2019/19] | Applicant(s) | For all designated states Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR | For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75016 Paris / FR | For all designated states Université Paris Diderot (Paris 7) 5 Rue Thomas Mann 75013 Paris / FR | For all designated states Université Paris Descartes 12, rue de l'Ecole de Médecine 75006 Paris / FR | For all designated states Université Pierre et Marie Curie (Paris 6) 4, Place Jussieu Tour Centrale 75005 Paris / FR | For all designated states Assistance Publique Hôpitaux de Paris 3 Avenue Victoria 75004 Paris / FR | [2016/33] | Inventor(s) | 01 /
DRAGON-DUREY, Marie-Agnès INSERM UMRS1138 Equipe 10 "Complément et maladies" 12 rue de l'Ecole de Médecine F-75006 Paris / FR | 02 /
SENANT, Marie Immunologie biologique Hôpital Européen Georges Pompidou 20 rue Leblanc F-75015 Paris / FR | [2016/33] | Representative(s) | Cabinet Nony 11 rue Saint-Georges 75009 Paris / FR | [N/P] |
| Former [2016/33] | Nony 11 rue Saint-Georges 75009 Paris / FR | Application number, filing date | 14780615.2 | 11.09.2014 | [2016/33] | WO2014IB64437 | Priority number, date | EP20130306251 | 12.09.2013 Original published format: EP 13306251 | [2016/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015036956 | Date: | 19.03.2015 | Language: | EN | [2015/11] | Type: | A1 Application with search report | No.: | EP3055695 | Date: | 17.08.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.03.2015 takes the place of the publication of the European patent application. | [2016/33] | Search report(s) | International search report - published on: | EP | 19.03.2015 | Classification | IPC: | G01N33/543, G01N33/564 | [2016/33] | CPC: |
G01N33/564 (EP,US);
G01N33/54306 (EP,US);
G01N33/6854 (US);
G01N33/94 (US);
G01N2496/00 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/33] | Title | German: | VERFAHREN ZUR IN-VITRO-QUANTIFIZIERUNG VON ALLOANTIKÖRPERN, AUTOANTIKÖRPERN UND/ODER THERAPEUTISCHEN ANTIKÖRPERN | [2016/33] | English: | METHOD FOR IN VITRO QUANTIFYING ALLO-ANTIBODIES, AUTO-ANTIBODIES AND/OR THERAPEUTIC ANTIBODIES | [2016/33] | French: | PROCÉDÉ D'ALLO-ANTICORPS DE QUANTIFICATION IN VITRO, D'AUTO-ANTICORPS ET/OU D'ANTICORPS THÉRAPEUTIQUES | [2016/33] | Entry into regional phase | 04.03.2016 | National basic fee paid | 04.03.2016 | Designation fee(s) paid | 04.03.2016 | Examination fee paid | Examination procedure | 04.03.2016 | Examination requested [2016/33] | 15.09.2016 | Amendment by applicant (claims and/or description) | 24.03.2017 | Despatch of a communication from the examining division (Time limit: M04) | 21.07.2017 | Reply to a communication from the examining division | 06.10.2017 | Despatch of a communication from the examining division (Time limit: M06) | 04.04.2018 | Reply to a communication from the examining division | 17.07.2018 | Despatch of a communication from the examining division (Time limit: M04) | 28.11.2018 | Application deemed to be withdrawn, date of legal effect [2019/19] | 03.01.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/19] | Fees paid | Renewal fee | 23.09.2016 | Renewal fee patent year 03 | 02.10.2017 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 30.09.2018 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2007007792 (EISAI R&D MAN CO LTD [JP], et al) [X] 1-6,8-13 * example 2 * [I] 14-17; | [I]US7824867 (WANG ZHUYING [US], et al) [I] 1-6,8-17 * column 1, line 44 - column 2, line 36; clolumn 12, lines 26-43; claims 1, 11-14; figures 1-6; column 6, line 14 - line 18 * * column 6, line 33 - line 43 ** column 11, line 53 - column 12, line 5; example 1 * | Examination | - EISAI R&D MAN CO LTD [JP]; YAMADA YUJI [JP], "WO2007007792 -Machine translated on 13-03-2017-", -, (20070118), pages 1 - 26, XP055353943 | - DAHLBOM I ET AL, "Protein A and protein G ELISA for the detection of IgG autoantibodies against tissue transglutaminase in childhood celiac disease", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 395, no. 1-2, doi:10.1016/J.CCA.2008.05.005, ISSN 0009-8981, (20080901), pages 72 - 76, (20080724), XP023179439 DOI: http://dx.doi.org/10.1016/j.cca.2008.05.005 | - Celikey Anonymous, "Celikey IgG FLUOROENZYMEIMMUNOASSAY FOR ANTI TISSUE TRANSGLUTAMINASE ANTIBODIES FOR IN VITRO DIAGNOSTIC USE- Manual of the kit", (20111117), pages 1 - 4, URL: http://www.inter-2t.phadia.com/PageFiles/29279/EliA Celikey IgG Well (2x12).pdf, (20171002), XP055411952 | by applicant | US3691016 | US3969287 | US4195128 | US4229537 | US4247642 | US4330440 | US4376110 | EP0451216 | EP0566647 | EP0682040 | US5530101 | US5877293 | US5886152 | EP0939127 | US6054297 | US7824867 | - VORECHOVSKY ET AL., AM. J HUM. GENET. GENETIC LINKAGE OF IGA DEFICIENCY TO THE MAJOR HISTOCOMPATIBILITY COMPLEX: EVIDENCE FOR ALLELE SEGREGATION DISTORSION, PARENT-OF-ORIGIN PENETRANCE DIFFERENCES, AND THE ROLE OF ANTI-IGA ANTIBODIES IN DISEASE PREDISPOSITION, (1999), vol. 64, pages 1096 - 1109 | - PLOSKI ET AL., "The genetic basis of Graves' disease", CURRENT GENOMICS, (2011), vol. 12, pages 542 - 563 | - LOSSIUS ET AL., "Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation", VIRUSES, (201212), vol. 4, no. 12, pages 3701 - 30 | - PIHOKER ET AL., "Auto-antibodies in diabetes", DIABETES, (200512), vol. 54, no. 2, pages 552 - 61 | - MAKKER ET AL., SEMIN. NEPHROL. IDIOPATHIC MEMBRANOUS NEPHROPATHY: AN AUTOIMMUNE DISEASE, (201107), vol. 31, no. 4, pages 333 - 340 | - SELMI ET AL., "Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis", J AUTOIMMUN., (201208), vol. 39, no. 1-2, pages 34 - 42 | - SAVAGE, "Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis", CLIN. EXP. IMMUNOL., (201105), vol. 164, no. 1, pages 23 - 26 | - PEDCHENKO ET AL., "Goodpasture's Disease: molecular architecture of the autoantigen provides clues to etiology and pathogenesis", CURR. OPIN. NEPHROL. HYPERTENS, (201105), vol. 20, no. 3, pages 290 - 296 | - MUSCAL; BREY, "Antiphospholipid syndrome and the brain in pediatric and adult patients", LUPUS., vol. 19, no. 4, pages 406 - 411 | - DRAGON-DUREY ET AL., "Clinical features of anti-factor H auto-antibody-associated hemolytic uremic syndrome", JAM. SOC. NEPHROL., (2010), vol. 21, pages 2180 - 2187 | - MERI ET AL., "Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis", J EXP. MED., (19920401), vol. 175, no. 4, pages 939 - 50 | - AMORNSIRIPANITCH ET AL., "Complement factor H autoantibodies are associated with early stage NSCLC", CLIN. CANCER RES., (2010), vol. 16, doi:doi:10.1158/1078-0432.CCR-10-0321, pages 3226 - 3231, XP055299396 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-10-0321 | - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525 | - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536 | - RIECHMANN ET AL., NATURE, (1988), vol. 322, pages 323 - 327 | - SINGER ET AL., J IMMUN., (1992), vol. 150, pages 2844 - 2857 | - MOUNTAIN ET AL., BIOTECHNOL. GENET. ENG. REV., (1992), vol. 10, pages 1 - 142 | - BEBBINGTON ET AL., BIOTECHNOLOGY, (1992), vol. 10, pages 169 - 175 | - KLINGER ET AL., "Immuno-pharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab", BLOOD, (20120628), vol. 119, no. 26, pages 6226 - 33 | - TOPP ET AL., "Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL", BLOOD, (20121220), vol. 120, no. 26, doi:doi:10.1182/blood-2012-07-441030, pages 5185 - 7, XP055142942 DOI: http://dx.doi.org/10.1182/blood-2012-07-441030 | - SALAUN, "Phase II trial of anti-carcino-embryonic antigen pre-targeted radio-immunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement", J NUCL. MED., (201208), vol. 53, no. 8, pages 1185 - 92 | - DAHLBOM ET AL., "Protein A and protein G ELISA for the detection of IgG autoantibodies against tissue transglutaminase in childhood celiac disease", CLIN. CHIM. ACTA., (200809), vol. 395, no. 1-2, doi:doi:10.1016/j.cca.2008.05.005, pages 72 - 6, XP023179439 DOI: http://dx.doi.org/10.1016/j.cca.2008.05.005 | - MURPHY ET AL., "Amplified expression and large-scale purification of protein L", BIOSEPARATION, (1996), vol. 6, no. 2, pages 107 - 1 | - J VIS EXP., (2010), page 1923 |